323 related articles for article (PubMed ID: 31082388)
1. Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.
Richmond CS; Vallatharasu Y; Deviley JA; Vos CR; Parsons BM; Kenny PA
Exp Mol Pathol; 2019 Oct; 110():104260. PubMed ID: 31082388
[TBL] [Abstract][Full Text] [Related]
2. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Ribas A; Lawrence D; Atkinson V; Agarwal S; Miller WH; Carlino MS; Fisher R; Long GV; Hodi FS; Tsoi J; Grasso CS; Mookerjee B; Zhao Q; Ghori R; Moreno BH; Ibrahim N; Hamid O
Nat Med; 2019 Jun; 25(6):936-940. PubMed ID: 31171879
[TBL] [Abstract][Full Text] [Related]
3. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Dummer R; Lebbé C; Atkinson V; Mandalà M; Nathan PD; Arance A; Richtig E; Yamazaki N; Robert C; Schadendorf D; Tawbi HA; Ascierto PA; Ribas A; Flaherty KT; Pakhle N; Campbell CD; Gusenleitner D; Masood A; Brase JC; Gasal E; Long GV
Nat Med; 2020 Oct; 26(10):1557-1563. PubMed ID: 33020648
[TBL] [Abstract][Full Text] [Related]
4. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
6. BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports.
Melin A; Routier E; Tissot H; Rouleau E; Robert C
Eur J Cancer; 2019 Nov; 121():109-112. PubMed ID: 31569065
[No Abstract] [Full Text] [Related]
7. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Ascierto PA; Ferrucci PF; Fisher R; Del Vecchio M; Atkinson V; Schmidt H; Schachter J; Queirolo P; Long GV; Di Giacomo AM; Svane IM; Lotem M; Bar-Sela G; Couture F; Mookerjee B; Ghori R; Ibrahim N; Moreno BH; Ribas A
Nat Med; 2019 Jun; 25(6):941-946. PubMed ID: 31171878
[TBL] [Abstract][Full Text] [Related]
8. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
9. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
Zia Y; Chen L; Daud A
Expert Opin Pharmacother; 2015; 16(14):2257-63. PubMed ID: 26331795
[TBL] [Abstract][Full Text] [Related]
10. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
12. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
14. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
15. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
Algazi AP; Othus M; Daud AI; Lo RS; Mehnert JM; Truong TG; Conry R; Kendra K; Doolittle GC; Clark JI; Messino MJ; Moore DF; Lao C; Faller BA; Govindarajan R; Harker-Murray A; Dreisbach L; Moon J; Grossmann KF; Ribas A
Nat Med; 2020 Oct; 26(10):1564-1568. PubMed ID: 33020646
[TBL] [Abstract][Full Text] [Related]
16. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
[No Abstract] [Full Text] [Related]
17. Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.
Green JS; Norris DA; Wisell J
Br J Dermatol; 2013 Jul; 169(1):172-6. PubMed ID: 23413975
[TBL] [Abstract][Full Text] [Related]
18. Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response.
Gonzalez-Cao M; Boada A; Teixidó C; Fernandez-Figueras MT; Mayo C; Tresserra F; Bustamante J; Viteri S; Puertas E; Santarpia M; Riso A; Barron F; Karachaliou N; Rosell R
Oncotarget; 2016 Aug; 7(35):56619-56627. PubMed ID: 27447748
[TBL] [Abstract][Full Text] [Related]
19. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
20. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H
Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
